Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PAREXEL Acquires Quantum Solutions India | Contract Pharma

What are you searching for?

Sign in
Breaking News

PAREXEL Acquires Quantum Solutions India

Expands safety management solutions

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PAREXEL International Corp. has signed a definitive agreement to acquire privately-owned Quantum Solutions India (QSI), a provider of specialized pharmacovigilance services based in Chandigarh. Financial terms were not disclosed. The acquisition is expected to close in early April, subject to customary closing conditions.
 
QSI was established in 2004, and provides a range of pharmacovigilance services, including individual case safety report processing, brand physician activities, affiliate support, aggregate report writing, literature reviews, and signal detection. The company has approximately 900 employees and services customers globally.
 
The QSI business will be integrated into PAREXEL’s Peri/Post-Approval Services group, which is part of the CRS segment, and is expected to contribute to PAREXEL’s Regulatory Outsourcing Services business within the Consulting segment.
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL said, “The acquisition of QSI will strengthen our capabilities in the growing field of outsourced safety management solutions, or pharmacovigilance. It will help us to create greater scale in this service area, and thereby enable us to provide a more comprehensive, efficient, and economical solution to clients around the world. Combined with the existing post-approval and regulatory strengths of PAREXEL, this acquisition will support the expansion of our pharmacovigilance services onto a broader platform. We are excited to be able to offer our clients QSI’s leading services through our Clinical Research Services business.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics